Company / SG&A Expense
BridgeBio Oncology Therapeutics, Inc. SG&A Expense History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$584.4K
FY2024
5-year range
$41.7K / $584.4K
FY2023-FY2024
Trend
+1301.7%
vs FY2023
Sector context
#213 of 213
Health Care
What the data says
Among 213 Health Care companies, BridgeBio Oncology Therapeutics, Inc. is in the top 0% for sg&a expense.
Based on SEC 10-K filings.
$584,389 in FY2024.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 0% in Health CareTop 0% of 213This company $584.4K Sector average $722.3M
▼
-99.9% below sector average
Key checks
Key Insights
- In FY2024, sg&a expense increased 1301.7% year-over-year.
- Ranks #213 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $584.4K | +1301.7% |
| FY2023 | $41.7K | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026